Skip to main content
← All trials
Recurrent Lung Non-Small Cell CarcinomaCancerLungs and breathingProcedureDrugBiologicalPhase 2

What this study is

This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes. Capmatinib and osimertinib are in a class of medications called kinase inhibitors. They work by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells and may help shrink tumors. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving capmatinib, osimertinib, and/or ramucirumab and targeting abnormal gene changes in tumor cells may be effective in shrinking or stabilizing advanced non-small cell lung cancer.

What's being tested

  • Biospecimen Collection

    Intervention · PROCEDURE

    Undergo collection of blood samples

  • Capmatinib

    Intervention · DRUG

  • Computed Tomography

    Intervention · PROCEDURE

    Undergo CT scan

  • Magnetic Resonance Imaging

    Intervention · PROCEDURE

    Undergo MRI

  • Osimertinib

    Intervention · DRUG

  • Ramucirumab

    Intervention · BIOLOGICAL

    Given IV

Both Capmatinib and Osimertinib

Given PO

Study details

Official title
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Sponsor
SWOG Cancer Research Network
Conditions
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Enrolling
66 people
Starts
2023-05-05
Est. completion
2028-06-30
Design
Open-label, randomized, parallel groups, Phase 2
Record
View on ClinicalTrials.gov ↗